Nuclear Imaging

Molecular imaging, also called nuclear imaging, includes positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. This section includes radiopharmaceuticals and tracers, PET-CT, SPECT-CT, and PET-MRI.

This figure highlights 3 patients with a final diagnosis of low-grade uptake (Perugini grade-1). Endomyocardial biopsy results were available for the patient depicted in Panel B demonstrating ATTR-CA as the underlying pathology.

News | Molecular Imaging

Nuclear Medicine Bone Scan Study Identifies Prevalence and Outcomes of Cardiac Amyloidosis

January 5, 2023 — A new study has determined that approximately three percent of all bone scan patients have markers of ...

January 04, 2023

Patients for Safer Nuclear Medicine calls NRC ruling a victory, notes work to protect patients is not over

News | Nuclear Imaging

Patient Coalition Applauds Federal Decision Impacting Nuclear Medicine Safety

January 2, 2023 — The federal agency that oversees the administration of nuclear medicine has announced that it will ...

January 02, 2023

IBA, a world leader in particle accelerator technology, today confirms that it has signed a contract with the Spanish Ministry of Health to install ten proton therapy systems across Spain as part of a significant public tender.

News | Proton Therapy

IBA Wins 10 Proton Therapy System Contract in Spain

January 2, 2023 — IBA, a world leader in particle accelerator technology, today confirms that it has signed a contract ...

January 02, 2023

Sponsored Content

Staging F-18 FDG PET/CT images of adenocarcinoma in the RUL of the lung illustrates the value of Vereos. The primary lesion in the right upper lobe appears in the upper row (PET image is left, CT image is right). A 3 mm synchronous primary or metastatic lesion in the RUL is apparent in the lower row. The precision afforded by Vereos' images provided the basis for the patient to undergo RUL lobectomy instead of thermal ablation of the primary lesion. Images courtesy of Dr. Jay Kikut and UVM

Blog | PET-CT

Digital PET Balances Scan Time and Resolution

Efficiency and effectiveness are inseparable in clinical medicine. Digital PET addresses them both. The key is the ...

October 25, 2018

Abhinav Jha to develop technique, test in patients with metastatic prostate cancer

News | Radiation Therapy

Imaging Technique May Measure Absorbed Dose from Radiation Therapy

December 22, 2022 — Patients with cancer that has spread to the bone are sometimes treated with alpha particle radiation ...

December 22, 2022

data showed that CytoSite’s Granzyme B (GzmB) PET imaging using [68Ga-NOTA]-hGZP (CSB-111) was feasible and safe in human subjects. These data come from a Phase I trial assessing the safety and feasibility of GzmB PET imaging in subjects with melanoma and non-small cell lung cancer (NSCLC) receiving KEYTRUDA (pembrolizumab).

News | Clinical Trials

CytoSite Bio Presents First-in-Human Data at Radiological Society of North American Annual Meeting

December 14, 2022 — CytoSite Bio, a company developing precision imaging products that determine patient response to ...

December 14, 2022

18F-rhPSMA-7.3 PET image showing multiple areas of uptake in the prostate gland in a man with newly diagnosed prostate cancer Photo courtesy of Blue Earth Diagnostics

News | Prostate Cancer

Blue Earth Diagnostics Announces Efficacy and Safety Results from Phase 3 LIGHTHOUSE Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Newly Diagnosed Prostate Cancer

December 2, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

December 02, 2022

A team led by UTHealth Houston's K. Lance Gould, MD, (center) used PET imaging technology (shown above) to map coronary blood flow and its outcomes among heart disease patients. (Photo by UTHealth Houston)

News | PET Imaging

PET Technology More Effective Than Angiogram at Determining Need for Coronary Stents, Bypass Surgery

December 1, 2022 — A new method for determining whether patients with heart disease need coronary stents or bypass ...

December 01, 2022

Researchers at the University of Wisconsin–Madison will kick off research scanning human subjects with GE Healthcare’s latest generation PCCT prototype in December 2022, representing the first U.S. clinical evaluation site with GE Healthcare’s pure silicon CT detector technology

News | Proton Therapy

UW–Madison To Perform the First U.S. Evaluation of GE Healthcare’s Photon Counting CT Technology with Deep Silicon Detectors

November 25, 2022 — Researchers at the University of Wisconsin–Madison, the first U.S. clinical evaluation site for GE ...

November 25, 2022

Simulations by Rice University engineers have revealed details about the molecular interactions between gadolinium contrast agents used in MRI scans and their liquid environment. In this model, green gadolinium is surrounded by blue chelate ions, themselves surrounded by water (gray oxygen and red hydrogen atoms). Thiago Pinheiro dos Santos/Rice University

News | Magnetic Resonance Imaging (MRI)

Rice Refines Analysis of MRI Contrast Agents

November 21, 2022 — You can keep your best guesses. Engineers at Rice University’s George R. Brown School of Engineering ...

November 21, 2022

Figure 1. The fat pad adjacent to the kneecap (Hoffa's fat pad, infrapatellar fat pad) can change in signal on MRI when the knee is inflamed. (A) Normal knee without signs of inflammation. (B) Arrow pointing on a circumscribed area with higher signal (bright lines) in the area of the fat pad (normally dark), which is indicative of a beginning inflammatory reaction. (C) The whole fat pad has a higher signal (light grey color with white lines), which is a sign of progressive inflammation of the knee joint.

News | RSNA

NSAIDs May Worsen Arthritis Inflammation

November 21, 2022 — Taking anti-inflammatory pain relievers like ibuprofen and naproxen for osteoarthritis may worsen ...

November 21, 2022

NorthStar Medical Radioisotopes’ Radiopharmaceutical CDMO in Beloit, Wis. (artist rendering). Upon completion, NorthStar will be first and only U.S. company housing commercial-scale, multi-radioisotope production and radiopharmaceutical development services on the same campus, enabling collaborating companies to realize logistical, regulatory and cost benefits. (Photo: Business Wire)

News | Radiopharmaceuticals and Tracers

NorthStar Medical Radioisotopes Expands Business Platform with New, Patient-focused, Radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) Services Unit

November 15, 2022 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

November 15, 2022

The American Society of Nuclear Cardiology has issued an alert about possible supply disruptions

News | Radiopharmaceuticals and Tracers

Alert: Mo-99/Tc-99m Supply Disruptions Possible

Nov. 4, 2022 — On October 28, the Nuclear Medicine Europe Emergency Response Team issued a statement about mechanical ...

November 05, 2022

18F-rhPSMA-7.3 PET image showing prostate cancer spread beyond the prostate region (Photo courtesy of Blue Earth Diagnostics)

News | PET Imaging

Blue Earth Diagnostics Announces Results on Clinical Factors Impacting Detection Rates from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer

November 2, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

November 02, 2022

Top trends boosting the industry expansion through 2028

Feature | Contrast Media | By Shankar Khatkale

Imaging Contrast Agents Global Market Outlook

According to a recent study from market research firm Graphical Research, the global imaging agents market size is set ...

November 02, 2022

UVA embedded links to their images and interactive radiology reports into Epic MyChart, allowing patients to review and share their Interactive Multimedia Reports and associated findings marked on live images through the hospital's patient portal.

Sponsored Content | Case Study | Enterprise Imaging

Improving Radiology Reporting and Workflow With Interactive Multimedia

Reporting produces the tangible work product of diagnostic radiologists. Reports should reflect the expertise of the ...

October 30, 2022

The oral presentation includes additional results from Blue Earth's Phase 3 SPOTLIGHT study evaluating the impact of clinical factors on the detection rate of 18F-rhPSMA-7.3 PET imaging in men with suspected prostate cancer recurrence based on elevated PSA following prior therapy

News | PET Imaging

Blue Earth Diagnostics Highlights Presentations on Axumin (Fluciclovine F 18) and Investigational 18F-rhPSMA-7.3 in Biochemically Recurrent Prostate Cancer

October 25, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

October 25, 2022

Company announces SCINTIX as new product name for its flagship biology-guided radiotherapy technology

News | PET-CT

RefleXion Highlights New Cancer Treatment Research Abstracts for Presentation at ASTRO 2022

October 24, 2022 — RefleXion Medical, a therapeutic oncology company pioneering biology-guided radiotherapy* (BgRT) as a ...

October 24, 2022

18F-SMBT-1 PET studies showed that beta-amyloid+ Alzheimer’s disease (AD) patients, but most importantly, beta-amyloid+ controls (CN) have significantly higher regional 18F-SMBT-1 binding than beta-amyloid- CN, with 18F-SMBT-1 retention highly associated with beta-amyloid burden. These findings suggest that increased 18F-SMBT-1 binding is detectable at the preclinical stages of beta-amyloid accumulation.

News | PET Imaging

Novel PET Imaging Agent Detects Earliest Signs of Alzheimer's Disease

October 20, 2022 — A new highly selective PET imaging agent can detect the presence of overexpressed monoamine oxidase-B ...

October 20, 2022

Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced the signing of a data-sharing agreement with Siemens Healthineers and the University Hospital of the Technical University of Munich (TUM) for anonymized 18F-rhPSMA-7.3 clinical data and images.

News | PET Imaging

Blue Earth Diagnostics Announces Data-sharing Agreement with Siemens Healthineers and the University Hospital of Technical University of Munich (TUM) for 18F-rhPSMA-7.3

October 19, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

October 19, 2022

Based on Spectrum Dynamics digital SPECT/CT platform, VERITON-CT 400 Series provides the benefits of increased sensitivity and throughput to clinical applications based on high energy isotopes used in Nuclear Medicine

News | SPECT-CT

World's First Digital SPECT/CT Capable of High Energy Imaging Enables Full Range of Clinical Capabilities to Nuclear Medicine Centers

October 18, 2022 — Spectrum Dynamics announced its newest development in digital nuclear medicine imaging: the ...

October 18, 2022